Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)

Fineline Cube Dec 26, 2024

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...

Company Drug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Fineline Cube Dec 26, 2024

China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...

Company Drug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

Fineline Cube Dec 26, 2024

China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials

Fineline Cube Dec 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...

Company Drug

CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...

Company Drug

Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial

Fineline Cube Dec 26, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...

Company

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District

Fineline Cube Dec 26, 2024

On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...

Company Drug

ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE

Fineline Cube Dec 26, 2024

China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...

Company Deals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Fineline Cube Dec 26, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...

Company Deals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Fineline Cube Dec 26, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...

Company Drug

Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies

Fineline Cube Dec 25, 2024

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...

Company Deals

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia

Fineline Cube Dec 25, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...

Company Deals

Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data

Fineline Cube Dec 25, 2024

UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...

Company Drug

Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review

Fineline Cube Dec 25, 2024

US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...

Company Drug

Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene

Fineline Cube Dec 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Dec 25, 2024

China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...

Company Deals

uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services

Fineline Cube Dec 25, 2024

China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...

Company Deals

WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC

Fineline Cube Dec 25, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...

Company Deals

Basecare Medical and SolarCare Form Alliance to Advance AI in IVF Services

Fineline Cube Dec 25, 2024

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a leading China-based in vitro fertilization (IVF) specialist,...

Posts pagination

1 … 291 292 293 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.